Market revenue in 2021 | USD 8.4 billion |
Market revenue in 2030 | USD 12.8 billion |
Growth rate | 4.7% (CAGR from 2021 to 2030) |
Largest segment | Anti-hypertensive |
Fastest growing segment | Hormones |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD billion |
Market segmentation | Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Anti-hypertensive was the largest segment with a revenue share of 15.48% in 2021. Horizon Databook has segmented the Japan branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the largest manufacturers of generic pharmaceuticals, which represents the world’s eighth largest market in terms of value. The growing geriatric population has increased the medical expenditure in the country.
To reduce the healthcare expenses, a cabinet decision was passed in 2015 with an aim to achieve generic drugs share of around 80% by September 2020. Due to the government efforts for higher use of generics, certain players are expanding their geographical presence and focusing on export of Japanese quality standard products back to their country to gain considerable profit margin.
Moreover, the drug pricing policy of the country is attractive for generic manufacturers, helping them establish their presence in the market. The National Health Insurance System in Japan sets the reimbursement price of generic drugs and biosimilar at 50% or less & 70%, respectively, than the originator drug.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan branded generics market , including forecasts for subscribers. This country databook contains high-level insights into Japan branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account